TrialSignal transduction and targeted therapy2025

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Xichun Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.